Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Michigan

Sites in Ann Arbor, MI

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1235
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Michigan, Ann Arbor, MI. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 121–132 of 1,235 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

EPPIC: Easing Pelvic Pain Interventions Clinical Research Program

NCT05127616
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Urologic Chronic Pelvic Pain Syndrome (UCPPS), Interstitial Cystitis, Bladder Pain Syndrome, Chronic Prostatitis, Chronic Pain, Chronic Pelvic Pain Syndrome, Chronic Overlapping Pain Disorders
Interventions
Minimal Contact-Cognitive Behavior Therapy, Patient Education/Support
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
Site status not listed — check the official record
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Not applicable Interventional

Transcranial Alternating Current Stimulation (tACS) in Stuttering

NCT06740968
Status at this site: Recruiting
View directory record Official record
Conditions
Stuttering, Adult, Stuttering, Childhood, Stuttering, Developmental
Interventions
transcranial alternating current stimulation (tACS)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374
Status at this site: Recruiting
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
93
States / cities
Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NCT02135042
Site status not listed — check the official record
View directory record Official record
Conditions
EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7
Interventions
Bone Scan, Cisplatin, Clinical Observation, Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Quality-of-Life Assessment
Procedure · Drug · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2034
U.S. locations
197
States / cities
Birmingham, Alabama • Tucson, Arizona • Auburn, California + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 1Phase 2 Interventional

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

NCT04643002
Status at this site: Recruiting
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
Site status not listed — check the official record
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
INCA036873
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting No phase listed Observational

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

NCT07556159
Status at this site: Recruiting
View directory record Official record
Conditions
Asthma
Interventions
Procedure: Investigational Procedures
Other
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

NCT06343805
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Myelofibrosis
Interventions
LY5830966
Drug
Lead sponsor
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Palo Alto, California • Tampa, Florida • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
Status at this site: Recruiting
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT
Recruiting Not applicable Interventional

AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE

NCT07277946
Status at this site: Recruiting
View directory record Official record
Conditions
Hernia
Interventions
ECLIPSIUM® System, Resorbable tacks (AbsorbaTack/SorbaFix)
Device
Lead sponsor
Tissium
Industry
Eligibility
22 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
12
States / cities
Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 12:01 PM EDT

About this University of Michigan institution page

What this page lists
ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.